請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89522完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蔡力凱 | zh_TW |
| dc.contributor.advisor | Li-Kai Tsai | en |
| dc.contributor.author | 羅彥伶 | zh_TW |
| dc.contributor.author | Yen-Ling Lo | en |
| dc.date.accessioned | 2023-09-08T16:09:30Z | - |
| dc.date.available | 2023-11-09 | - |
| dc.date.copyright | 2023-09-08 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-08-05 | - |
| dc.identifier.citation | 1.Lippi, G., F. Sanchis-Gomar, and G. Cervellin, Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke, 2021. 16(2): p. 217-221.
2.Chiang, C.E., et al., 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc, 2016. 115(11): p. 893-952. 3.Seiffge, D.J., et al., Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol, 2019. 18(1): p. 117-126. 4.European Heart Rhythm, A., et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010. 31(19): p. 2369-429. 5.Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study. Stroke, 1991. 22(8): p. 983-988. 6.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994. 154: p. 1449–1457. 7.Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators; Daniel E Singer, R.A.H., Daryl R Gress, Mary A Sheehan, Lynn B Oertel, Sue Ward Maraventano, Dyan Ryan Blewett, Bernard Rosner, J Philip Kistler, The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med, 1990. 323: p. 1501-1511. 8.Antani, M.R., et al., Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med, 1996. 11(12): p. 713-20. 9.Albers, G.W., et al., Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology, 1997. 48(6): p. 1598-604. 10.Bungard TJ, G.W., Teo KK, McAlister FA, Tsuyuki RT, Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med, 2000. 160. 11.Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg, 2016. 50(5): p. e1-e88. 12.Stuart J Connolly , M.D.E., Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A Reilly, Ellison Themeles, Jeanne Varrone, Susan Wang, Marco Alings, Denis Xavier, Jun Zhu, Rafael Diaz, Basil S Lewis, Harald Darius, Hans-Christoph Diener, Campbell D Joyner, Lars Wallentin; RE-LY Steering Committee and Investigators, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009. 361(12): p. 1139-1151. 13.Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011. 365(11): p. 981-92. 14.Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011. 365(10): p. 883-91. 15.Giugliano, R.P., et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013. 369(22): p. 2093-104. 16.Ruff, C.T., et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014. 383(9921): p. 955-62. 17.Powers, W.J., et al., Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2019. 50(12): p. e344-e418. 18.Ya-Ju Lin, Y.-T.H., Pai-Ching Tsui, Li-Kai Tsai, Chih-Ping Chung, Shu-Fan Kuo, Pi-Shan Sung, Helen L. Po, Taiwan Stroke Society Guideline Consensus Group, 2019 Taiwan Stroke Society Guideline on the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation. Formosan Journal of Stroke, 2019. 1(3): p. 143-184. 19.D'Amelio, M., et al., Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke. J Stroke Cerebrovasc Dis, 2014. 23(4): p. 649-54. 20.Lindley, R.I., et al., Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis, 2004. 13(6): p. 235-46. 21.Purrucker, J.C., et al., Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants. J Stroke, 2017. 19(1): p. 67-76. 22.van Kranendonk, K.R., et al., Hemorrhagic transformation is associated with poor functional outcome in patients with acute ischemic stroke due to a large vessel occlusion. J Neurointerv Surg, 2019. 11(5): p. 464-468. 23.Steffel, J., et al., 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021. 23(10): p. 1612-1676. 24.Ya-Ju Lin, Y.-T.H., Pai-Ching Tsui, Li-Kai Tsai, Chih-Ping Chung, Shu-Fan Kuo, Pi-Shan Sung, Helen L. Po, Taiwan Stroke Society Guideline Consensus Group, 2019 Taiwan Stroke Society Guideline on the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation. Formosan Journal of Stroke, 2019. 1(3): p. 143 - 184. 25.stroke, N.c.g.f., National Clinical Guideline for Stroke for the UK and Ireland. London: Intercollegiate Stroke Working Party. 2023 May 4: https://www.strokeguideline.org. 26.Julian P T Higgins, S.G.T., Jonathan J Deeks, Douglas G Altman, Measuring inconsistency in meta-analyses. BMJ, 2003. 327(7414): p. 557–560. 27.Hong, K.S., et al., Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation–related mild ischemic stroke: A randomized clinical trial. JAMA Neurology, 2017. 74(10): p. 1206-1215. 28.Labovitz, A.J., et al., Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial. Stroke, 2021. 52(4): p. 1164-1171. 29.Oldgren, J., et al., Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation, 2022. 146(14): p. 1056-1066. 30.Fischer, U., et al., Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med, 2023. 31.Cappellari, M., et al., Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis, 2016. 42(3): p. 393-8. 32.Wilson, D., et al., Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: Multicentre cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2019. 90(3): p. 320-325. 33.Al Bakr, A.I., et al., Timing to start anticoagulants after acute ischemic stroke with non-valvular atrial fibrillation. J Neurol Sci, 2020. 409: p. 116582. 34.D'Anna, L., et al., Early initiation of direct anticoagulation after stroke in patients with atrial fibrillation. European Journal of Neurology, 2020. 27(11): p. 2168-2175. 35.Yaghi, S., et al., Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. Stroke, 2020. 51(9): p. 2724-2732. 36.De Marchis, G.M., et al., Early versus late start of direct oral anticoagulants after acute ischaemic stroke linked to atrial fibrillation: an observational study and individual patient data pooled analysis. J Neurol Neurosurg Psychiatry, 2022. 93(2): p. 119-125. 37.Kimura, S., et al., Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke, 2022. 53(5): p. 1540-1549. 38.Sterne, J.A., et al., Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 2011. 343: p. d4002. 39.Smythe, M.A., et al., Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. Pharmacotherapy, 2020. 40(1): p. 55-71. 40.Toyoda, K., et al., Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke, 2015. 10(6): p. 836-42. 41.Seiffge, D.J., et al., Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology, 2016. 87(18): p. 1856-1862. 42.Paciaroni, M., et al., Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke, 2015. 46(8): p. 2175-82. 43.Wein, T., et al., Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke, 2018. 13(4): p. 420-443. 44.Steffel, J., et al., The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018. 20(8): p. 1231-1242. 45.Klijn, C.J., et al., Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J, 2019. 4(3): p. 198-223. 46.Hindricks, G., et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J, 2021. 42(5): p. 373-498. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89522 | - |
| dc.description.abstract | 1.研究背景
對於心房顫動 (AF) 患者而言，關於什麼時候以及如何在急性缺血性中風時，開始使用warfarin或新型口服抗凝血劑 (NOAC)，至今仍沒有最佳策略。目前指引對於心房顫動患者於缺血性中風發作後，起始口服抗凝治療的時間和方法仍不一致且缺乏具體建議。儘管一些回顧性和觀察性研究探討了早期使用NOAC的利弊，但這些研究的方法學和結論不盡相同，因此何時需起始口服抗凝血劑此問題仍然存在於臨床實務中，非常需要統合分析及更多大型隨機對照試驗來提供更具說服力的證據。 2.研究方法 由PubMed及Scopus電子資料庫平台收尋相關醫學文獻，共可得到204篇文章。我們依照設定的納入及排除條件後，共獲得4篇隨機的臨床試驗與7篇觀察性研究可進入系統性文獻回顧以進行統合分析。這些隨機分派性臨床試驗及觀察性研究，皆分析給予口服抗凝血劑後之預後，包括複合性預後指標、再次復發的缺血性中風或顱內出血(ICH)的相關風險。 3.研究結果 在包含4個隨機對照試驗及3個觀察性研究的整體分析中，8,874名心房顫動患者於急性缺血性腦中風後接受了NOACs或warfarin 的治療，不論在固定效應模型 (相對風險: 0.74; 95%信賴區間: 0.61-0.89) 或者隨機效應模型 (相對風險: 0.75; 95%信賴區間: 0.58-0.96)的統合分析皆顯示，早期給藥較晚期給藥顯著減少複合式預後指標。而針對次級指標，在4個隨機對照試驗及6個觀察性研究的10,743名心房顫動患者中，不論在固定效應模型 (相對風險: 0.71; 95%信賴區間: 0.58-0.87) 或隨機效應模型 (相對風險: 0.72; 95%信賴區間: 0.51-0.91)的統合分析，亦皆顯示早期給藥較晚期給藥顯著減少復發性缺血性腦中風。而於4個隨機對照試驗及6個觀察性研究的10,002名心房顫動患者，在固定效應模型 (相對風險: 0.87; 95%信賴區間: 0.65-1.18) 或隨機效應模型 (相對風險: 0.91; 95%信賴區間: 0.67-1.22) 的統合分析皆顯示早期給藥和晚期給藥之顱內出血風險相似。 若僅侷限於4個隨機對照試驗進行統合分析，3,172 名心房顫動患者於急性缺血性中風後接受了NOACs 或warfarin的治療，在固定效應模型的統合分析顯示，早期給藥較晚期給藥顯著減少了複合式預後指標 (相對風險: 0.80; 95%信賴區間: 0.64-0.99)；但於隨機效應模型分析上並無顯著 (相對風險: 0.83; 95%信賴區間: 0.67-1.01)。近一步分析，3,134 名心房顫動患者發生復發性缺血性中風的風險，無論在固定效應模型(相對風險: 0.71; 95%信賴區間: 0.53-0.96)或隨機效應模型(相對風險: 0.73; 95%信賴區間: 0.55-0.99)的統合分析，早期給藥皆較晚期給藥顯著減少了復發性缺血性中風的可能性。而於2,246名心房顫動患者中，在固定效應模型(相對風險: 1.07; 95%信賴區間: 0.70-1.65)或隨機效應模型(相對風險: 1.08; 95%信賴區間: 0.71-1.67)的統合分析皆顯示早期給藥和晚期給藥之顱內出血風險相似。 而若僅侷限於7個隨機對照試驗進行統合分析，5,702名心房顫動患者於急性缺血性中風後接受了NOACs或warfarin的治療，在固定效應模型的統合分析顯示，早期給藥較晚期給藥顯著減少了複合式預後指標 (相對風險: 0.63; 95%信賴區間: 0.44-0.90)；但於隨機效應模型分析上並無顯著 (相對風險: 0.63; 95%信賴區間: 0.32-1.24)。而針對次級預後指標，於7,609名心房顫動患者在固定效應模型的統合分析顯示，早期給藥較晚期給藥顯著減少了復發性缺血性腦中風指標 (相對風險: 0.71; 95%信賴區間: 0.54-0.94)，但於隨機效應模型分析上並無顯著 (相對風險: 0.78; 95%信賴區間: 0.51-1.20)。而於7,756名心房顫動患者，在固定效應模型(相對風險: 0.75; 95%信賴區間: 0.49-1.12)或隨機效應模型(相對風險: 0.77; 95%信賴區間: 0.51-1.16)的統合分析皆顯示早期給藥和晚期給藥之顱內出血風險相似。 4.研究結論 在心房顫動的急性缺血性腦中風患者，於中風後早期給予口服抗凝血劑比延後給予藥物治療，可能可以減少整體的不良預後。其中早期給予抗凝血藥物似乎可降低復發性缺血性中風的發生率，且無增加中風後出血發生的機會。 | zh_TW |
| dc.description.abstract | 1. Background
There is no optimal strategy for when and how to initiate warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) in acute ischemic stroke in patients with atrial fibrillation (AF). Current guidelines are inconsistent and lack specific recommendations for when and how to initiate oral anticoagulant therapy after onset of ischemic stroke in patients with AF. Some retrospective and observational studies discussing early use of anticoagulants in acute stroke have shown inconsistent results; therefore, this clinical relevant issue remains requiring further meta-analysis and large randomized controlled trials to provide more convincing evidence. 2. Method Relevant literature was collected from the PubMed and Scopus electronic database platforms. After obtaining a total of 204 literature, we followed the set inclusion and exclusion criteria, and obtained a total of 4 randomized clinical trials (RCTs) and 7 observational studies for further meta-analysis. They analyzed the outcome after using oral anticoagulants at early or late stage upon acute ischemic stroke, focusing on composite outcome, recurrent ischemic stroke, and intracranial hemorrhage. 3. Results In 4 RCTs and 7 observational studies of 8,874 patients with AF upon acute ischemic stroke, early initiation of NOACs or warfarin showed a significant reduction in composite outcome using the fixed-effects model (RR: 0.74; 95% CI: 0.61-0.89) or the random-effects model (RR: 0.75; 95% CI: 0.58-0.96) as compared to delayed administration of anticoagulants. In 10,743 patients with AF and acute ischemic stroke, early initiation of NOACs or warfarin resulted in a significant reduction in recurrent ischemic stroke using the fixed-effects model (RR: 0.71; 95% CI: 0.58-0.87) and the random-effects model (RR: 0.72; 95% CI: 0.51-0.91) than delayed anticoagulation. On the other hand, in 10,002 patients with AF, there was no significant difference in the risk of intracranial hemorrhage in both fixed-effects model (RR: 0.87; 95% CI: 0.65-1.18) and random-effects model (RR: 0.91; 95% CI: 0.67-1.22). We further analyzed RCTs alone. Among 3,172 participants with AF upon acute ischemic stroke, early administration of anticoagulants showed significantly lower risk to develop events of composite outcome than late administration in the fixed effect model (RR: 0.80; 95% CI: 0.64-0.99) but only a trend toward lower risk for early administration of anticoagulants in the random effects model to achieve composite outcome (RR:0.83; 95% CI: 0.67-1.01). In the secondary outcome, there was lower risk of recurrent ischemic stroke for early than delayed initiation of anticoagulants for 3,134 patients in both fixed effect model (RR: 0.71; 95% CI: 0.53-0.96) and random effects model (RR: 0.73; 95% CI: 0.55-0.99). Notably, in 2,246 patients with AF, there was no significant difference in the risk of intracranial hemorrhage in both fixed-effects model (RR: 1.07; 95% CI: 0.70-1.65) and random-effects model (RR: 1.08; 95% CI: 0.71-1.67). We also analyzed observational studies alone. Among 5,702 participants with AF upon acute ischemic stroke, early initiation of NOACs or warfarin significantly reduced the composite outcome according to the fixed-effects model (RR: 0.63; 95% CI: 0.44-0.90); the random-effects model analysis did not show a statistically significant reduction in the composite outcome for the early initiation group (RR: 0.63; 95% CI: 0.32-1.24). Besides, in 7,609 patients, early compared to delayed initiation of NOACs or warfarin significantly reduced the risk of recurrent ischemic stroke according to the fixed-effects model (RR: 0.71; 95% CI: 0.54-0.94) but not the random-effects model (RR: 0.78; 95% CI: 0.51-1.20). Finally, in 7,756 patients, there was no significant difference in the risk of intracranial hemorrhage in both fixed-effects model (RR: 0.75; 95% CI: 0.49-1.12) and random-effects model (RR: 0.77; 95% CI: 0.51-1.16). 4. Conclusion In patients with AF-related acute ischemic stroke, our meta-analysis demonstrated that early initiation of anticoagulation is likely better than delayed administration regarding composite outcome and secondary outcome of recurrent ischemic stroke without influence on the risk of intracranial hemorrhage. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-08T16:09:30Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2023-09-08T16:09:30Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
謝辭 ii 中文摘要 iii Abstract vi Content x List of Figures xii List of Tables xiii 1. Introduction 1 2. Methods 4 2.1 Search methodology and study selection criteria 4 2.2 Data Extraction 5 2.3 Risk of bias assessment 6 2.4 The process of data synthesis and statistical analysis 6 3. Results 6 3.1 Included studies 6 3.2 The characteristics of four RCTs 7 3.3 Quality assessment 8 3.4 The characteristics of seven observational studies 8 3.5 Outcomes from RCTs and observational studies 9 3.6 Outcome from RCTs 10 3.7 Outcome of observational studies 12 3.8 Publication bias 13 4. Discussion 13 5. Conclusion 18 Reference 40 Appendix: Clinical Trial Protocol 48 | - |
| dc.language.iso | en | - |
| dc.title | 急性缺血性中風後心房顫動患者的早期或延遲抗凝治療： 系統性回顧和統合分析與臨床試驗計畫書 | zh_TW |
| dc.title | Early or Delayed Anticoagulation in Patients with Atrial Fibrillation upon Acute Ischemic Stroke: A Systematic Review, Meta-Analysis and Protocol | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 111-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 楊偉勛;蔡欣熹 | zh_TW |
| dc.contributor.oralexamcommittee | Wei-Shiung Yang;Hsin-Hsi Tsai | en |
| dc.subject.keyword | 心房顫動,早期使用,晚期使用,缺血性中風,顱內出血,抗凝血劑, | zh_TW |
| dc.subject.keyword | Atrial fibrillation,early,delay,ischemic stroke,intracranial hemorrhage,anticoagulants, | en |
| dc.relation.page | 80 | - |
| dc.identifier.doi | 10.6342/NTU202302981 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2023-08-07 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 臨床醫學研究所 | - |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-111-2.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 3.59 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。